Abstract: The present invention relates to novel hydroxy-containing alkyl glycamide surfactants and detergent composition comprising said surfactants. Since they surprisingly provide low foam, these surfactants can be used as cleansing surfactants in applications where low foaming is desirable.

Abstract: Tropyl 7-azaindol-3-ylcarboxamides of the formula ##STR1## or their N-oxides of the formula ##STR2## wherein R is hydrogen, alkyl, cyclo-alkyl, arylalkyl or acyl, are particularly effective as antitussive agents.

Abstract: A compound in all possible racemic, enantiomeric and diastereoisomer forms of the formula ##STR1## wherein Y is --O--, Z.sub.2 is --CF.sub.3, Z.sub.1 is --CN or --NO.sub.2, X is --O-- or --S--, R.sub.3 is hydrogen or alkyl of 1 to 4 carbon atoms optionally substituted by at least one halogen or --CN and R.sub.4 and R.sub.5 are individually alkyl of 1 to 4 carbon atoms optionally substituted with a member of the group consisting of halogen, --OH, esterified or etherified or protected hydroxy and phenylthio optionally substituted by halogen or --OH, and wherein at least one of R.sub.4 and R.sub.5 is substituted having antiandrogenic activity.

Abstract: This invention relates to certain novel compounds and derivatives thereof, their synthesis, and their use as selective alpha 1b adrenergic receptor antagonists. These compounds display submicromolar affinity for the human alpha 1b adrenergic receptor subtype while displaying at least five-fold lower affinity for the human alpha 1d and alpha 1a adrenergic receptor subtypes, and many other G-protein coupled human receptors. One application of these compounds is in the treatment of hypertension. More specifically, these compounds display selectivity for lowering blood pressure without, for example, substantially affecting urethral pressure.

Abstract: The invention relates to substituted ethyl .alpha.,.alpha.-diarylmethyl ether derivatives and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising the same, and methods of treating cocaine addiction and overdose, and diseases and conditions characterized by abnormal dopaminergic neurotransmission, using the same.

Abstract: The present invention provides a compound having the structure: ##STR1## wherein X, Y, and Z are independently H, Cl, Br, F, OCH.sub.3, I, or an alkyl group having 1 to 6 carbon atoms; and R is ##STR2## wherein n is 0 to 6, X' and Y' are independently H, Cl, F, CH.sub.3, C.sub.2 H.sub.5, C.sub.3 H.sub.7, C.sub.4 H.sub.9, OCH.sub.3, OH, CF.sub.3, OCF.sub.3, NO.sub.2, NH.sub.2, N(CH.sub.3).sub.2, NHCOCH.sub.3, NCS, NHCOCH.sub.2 Br, or N.sub.3, and (CH.sub.2).sub.n, if present, may be substituted with OH, OCH.sub.3, or an alkyl or alkenyl group having 1 to 3 carbon atoms. The present invention also provides a pharmaceutical composition comprising the compound above and a pharmaceutically acceptable carrier. The present invention further provides a method for treating a disease characterized by a dopamine deficiency which comprises administering to a subject in need of such treatment an amount of the pharmaceutical composition above effective to treat the disease.

Abstract: The invention relates to novel uracil derivatives having excellent inhibiting effects of human derived thymidine phosphorylase and anti-tumor activity. The pharmaceutical compositions, anti-tumor potentiators, antitumor agents containing such novel compounds, and a process for their preparation and use is described.

Abstract: The present invention relates to new compounds which are useful as ultraviolet absorbing agents (UVAs) and as fluorescent whitening agents (FWAs), and to a method of improving the sun protection factor (SPF) of textile fibre material, especially cotton, polyamide and wool, treated with the new compounds and with certain known compounds.

Abstract: The invention provides Form II, a pharmaceutically elegant, stable polymorph of olanzapine useful for treating a condition selected from the group consisting of a psychotic condition, mild anxiety and gastrointestinal conditions.

Abstract: Pyrimidine derivatives useful as a gastrointestinal prokinetic agent, represented by formula ##STR1## wherein X is O or NR.sup.5, Y is O, S or NR.sup.5 wherein R.sup.5 is a hydrogen atom, a C.sub.1 -C.sub.6 alkyl group or the like;R.sup.1 and R.sup.2 may be the same or different and each is a hydrogen atom, a C.sub.1 -C.sub.6 alkyl group or the like;R.sup.3 is CN, or COOR.sup.6 wherein R.sup.6 is a C.sub.1 -C.sub.6 alkyl group, a C.sub.3 -C.sub.6 cycloalkyl group, an aryl group or the like;R.sup.4 is --SR.sup.7 or --NR.sup.8 R.sup.9 wherein R.sup.7 is a C.sub.1 -C.sub.6 alkyl group;R.sup.8 is a C.sub.1 -C.sub.6 alkyl group or the like;R.sup.9 is a hydrogen atom, a C.sub.1 -C.sub.6 alkyl group or the like, or R.sup.8 and R.sup.9 may represent, together with the nitrogen atom to which they are attached, an N-substituted piperazine ring of formula (X) ##STR2## wherein R.sup.10 represents a C.sub.1 -C.sub.6 alkyl group or the like or a pharmacologically acceptable salt thereof.

Abstract: The invention provides hydroxamic acid derivatives of the general formula ##STR1## wherein R.sup.1 represents cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl; R.sup.2 represents a saturated 5- to 8-membered monocyclic or bridged N-heterocyclic ring, which N-heterocyclic ring is attached via the N atom and when it is monocyclic, optionally contains NR.sup.4, O, S, SO or SO.sub.2 as a ring member and/or is optionally substituted on one or more C atoms by hydroxy, lower alkyl, lower alkoxy, oxo, ketalized oxo, amino, mono(lower alkyl)amino, di(lower alkyl)amino,carboxy, lower alkoxycarbonyl, hydroxy-methyl, lower alkoxymethyl, carbamoyl, mono(lower alkyl)-carbamoyl, di(lower alkyl)carbamoyl or hydroxyimino; R.sup.3 represents a 5- or 6-membered N-heterocyclic ring which (a) is attached via the N atom, (b) optionally contains N, O and/or S, SO or SO.sub.

Abstract: A phthalide compound represented by formula (I) and a recording material containing the phthalide compound: ##STR1## wherein Ar represents a substituent represented by one of formulas (II-1), (II-2) and (III), and the other symbols in formula (I) are defined in the specification: ##STR2##

Abstract: A gel hand cleaner consists essentially of d-limonene, a solvent, C-11 alcohol ethoxylate, polyoxyethylene (20) sorbitan monooleate, a water-soluble acrylic polymer, sodium hydroxide, mixed isothiazolinones, 2,6-di-tert-butyl-p-cresol, and the balance, water.

Abstract: This invention relates to substituted dihydropyridazinones, pyridazinones and related compounds, of the formula ##STR1## wherein A, Q, D and R1 are as defined within, compositions containing these compounds and methods of controlling agricultural and mammalian fungal diseases.

Abstract: Natural or synthetic wax dissolved in the continuous organic phase of an water-in-oil emulsion retards evaporation of water from a dispersed aqueous phase. An in situ prepared equilibrium mixture of benzyl alcohol, formic acid and benzyl formate emulsified with oleic hydroxyethyl imidazoline or similar oil soluble emulsifying agent is thickened with hydroxypropyl cellulose or hydroxypropyl methylcellulose and contains 0.1 to 1.0% by weight paraffin wax with a melting point of 47.degree. to 65.degree. C. Wax dissolved in the organic phase retards evaporation of water, and formic acid or ammonia which are very volatile in comparison with benzyl alcohol forming the major component of the organic phase. A petroleum distillate is used to pre-wet a hydroxypropyl cellulose thickener and dissolve the wax.

Abstract: This invention relates to substituted dihydropyridazinones, pyridazinones and related compounds, of the formula ##STR1## wherein A, Q, D and R1 are as defined within, compositions containing these compounds and methods of controlling agricultural and mammalian fungal diseases.

Abstract: The invention relates to a novel process to prepare 1,4-dihydropyridines and in particular amlopidine and in novel intermediates obtained during the synthesis of the 1,4-dihydropyridines which have potential activity as antihypertensive agents.

Abstract: Benzofurans of the formula I ##STR1## and their salts in whichR.sup.1, R.sup.2 and X have the meanings indicated in claim 1, are suitable as intermediates in the synthesis of medicaments and show effects on the central nervous system.

Abstract: The invention pertains to a cleaning mixture for use in cleaning concrete pads. The mixture consists of two components and each of the two components has two ingredients. The first ingredient of the first component consists of an OIL-DRI -type all purpose absorbent clay material while the second ingredient is a cat litter or an addapolgite-type clay. Both of the ingredients of the first component are of a granular material. The second component also has two ingredients, the first is a Kaolin-type clay and the second ingredient is a finely ground clay dust. The first component, when applied to the surface of a contaminated concrete, will loosen and break up the hardened oil or grease deposit while the ingredients of the second component, when applied to the concrete surface after the the residue of the first component has been removed will absorb the oil from the pores and crevices of the concrete and apply a whitening effect to the concrete and also will seal the pores and the crevices of the concrete.

Abstract: Cysteine protease inhibitors which deactivate the protease by covalently bonding to the cysteine protease and releasing the enolate of a 1,3-dicarbonyl (or its enolic form). The cysteine protease inhibitors of the present invention accordingly comprise a first portion which targets a desired cysteine protease and positions the inhibitor near the thiolate anion portion of the active site of the protease, and a second portion which covalently bonds to the cysteine protease and irreversibly deactivates that protease by providing a carbonyl or carbonyl-equivalent which is attacked by the thiolate anion of the active site of the cysteine protease to sequentially cleave a .beta.-dicarbonyl enol ether leaving group.